BioStock Studio: Alligator Bioscience's long-term value driver

Alligator Bioscience has just announced that it is carrying out a rights issue worth approximately 257 million SEK. CEO Søren Bregenholt came by the BioStock Studio to discuss the main goals with this capital raise and how Alligator's lead candidate mitazalimab has become a long-term value driver for the company. 

Watch the full Q&A with Alligator Bioscience's CEO Søren Bregenholt at https://www.biostock.se/en/:

https://www.biostock.se/en/2021/10/biostock-studio-alligator-biosciences-long-term-value-driver/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/